Regulus Therapeutics Inc.
Investor Relations Department
10614 Science Center Dr
San Diego, CA 92121
United States

Visit IR website
Sign-up for Email alerts

NASDAQ: RGLS	
Last Trade:	1.65
Trade Time:	4:00 PM ET Mar 29, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	0.94 - 8.90
Volume	12,100

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting *micro*RNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced *micro*RNA therapeutics pipeline complemented by a maturing *micro*Markers℠ biomarkers platform and a rich intellectual property estate to retain its leadership in the *micro*RNA field. Regulus is developing RG-101, a GalNAc-conjugated anti-miR targeting *micro*RNA-122 for the tre... (more)

Stock Performance



Press Releases [View all]

Mar 28, 2017
Regulus to Present at the 16th Annual Needham Healthcare Conference

Mar 2, 2017
Regulus Reports Fourth Quarter 2016 Financial Results and Pipeline Update

Feb 23, 2017
Regulus to Release Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017

Feb 16, 2017
Regulus Announces Publication in Nature Communications Identifying miR-17 as a Promising Drug Target for ADPKD

Feb 8, 2017
Regulus to Present at Upcoming Healthcare Conferences

Financials [View all]

Fourth Quarter Financial Results

Mar 3, 2017
Annual Report (10-K)

Apr 22, 2016
Proxy Statement (DEF 14A)

Nov 2, 2016
Quarterly Report (10-Q)

Aug 3, 2016
Quarterly Report (10-Q)

May 3, 2016
Quarterly Report (10-Q)